Methods of expressing chimeric mouse and human CD40 ligand...

Details Methods of expressing chimeric mouse and human CD40 ligand... Methods of expressing chimeric mouse and human CD40 ligand...

2006-07-04

2006-07-04

Gambel, Phillip (Department: 1644)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S093100, C424S093710, C424S093200, C424S093700, C435S440000, C435S455000, C435S252300, C435S320100, C435S325000, C536S023100, C536S023400, C536S023500

Reexamination Certificate

active

07070771

ABSTRACT:
This invention relates to genes which encode accessory molecule ligands, such as the CD40 ligand and their use for immunomodulation, vaccination and treatments of various human diseases, including malignancies and autoimmune diseases. This invention also describes the use of accessory molecule ligands which are made up of various domains and subdomain portions of molecules derived from the tumor necrosis factor family. The chimeric molecules of this invention contain unique properties which lead to the stabilization of their activities and thus greater usefulness in the treatment of diseases. Vectors for expressing genes which encode the accessory molecule ligands of this invention are also disclosed.

REFERENCES:
patent: 4990455 (1991-02-01), Yamagishi et al.
patent: 5422104 (1995-06-01), Fiers et al.
patent: 5480981 (1996-01-01), Goodwin et al.
patent: 5486463 (1996-01-01), Lesslauer et al.
patent: 5519119 (1996-05-01), Yamada et al.
patent: 5540926 (1996-07-01), Aruffo et al.
patent: 5565321 (1996-10-01), Spriggs et al.
patent: 5573924 (1996-11-01), Beckmann et al.
patent: 5606023 (1997-02-01), Chen et al.
patent: 5817516 (1998-10-01), Kehry et al.
patent: 5861310 (1999-01-01), Freeman et al.
patent: 6016832 (2000-01-01), Vars et al.
patent: 6017527 (2000-01-01), Maraskovsky et al.
patent: 0 317 641 (1989-05-01), None
patent: 0 585 943 (1993-03-01), None
patent: 0 675 200 (1995-10-01), None
patent: WO 96 18413 (1996-06-01), None
patent: 1 016 721 (2000-07-01), None
patent: WO 91 02540 (1991-03-01), None
patent: WO 93/08207 (1993-04-01), None
patent: WO 94/04570 (1994-03-01), None
patent: WO 94 04680 (1994-03-01), None
patent: WO 94/17196 (1994-08-01), None
patent: WO 95/17202 (1995-06-01), None
patent: WO 95 18819 (1995-07-01), None
patent: WO 95 32627 (1995-12-01), None
patent: WO 96/14876 (1996-05-01), None
patent: WO 98 21232 (1998-05-01), None
Skolnick Trends in Biotechnology 18:34-39 (2000).
NGO et al. In the Protein Folding Problem and Tertiary Structure Prediction 1994 Merz et al (ED) Birkhauser Beuton MA pp. 433, 492-495.
Yellin et al. J. Immunol. 153: 666-674 (1994).
Alderson et al. J Exp. Med. 178: 669-674 (1993).
Nadler, Lee M., “The Malignant Lymphomas,”Harrison's Principles of Internal Medicine, Wilson et al., eds., McGraw-Hill, New York, Chapter 302, pp. 1599-1612.
Thomas, J. Alero et al., “Epstein-Barr Virus-Associated Lymphoproliferative Disorders in Immunocompromised Individuals,”Advances in Cancer Research, Woude et al., eds., Academic Press, Inc., 57:329-380 (1991).
Fanslow, William C. et al., “Structural characteristics of CD40 ligand that determine biological function,”Seminars in Immunology, 6:267-278 (1994).
Armitage, Richard J. et al., “Molecular and biological characterization of a murine ligand for CD40,”Nature, 357:80-82 (1992).
Hollenbaugh, Diane et al., “The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity,”The EMBO Journal, 11:4313-4321 (1992).
Zhang, Haidi et al., “Amelioration of Collagen-induced Arthritis by CD95 (Apo-1/Fas)-ligand Gene Transfer,”J. Clin. Invest., 100:1951-1957 (1997).
Wiley, James A. et al., “Exogenous CD40 Ligand Induces a Pulmonary Inflammation Response,”Journal of Immunology, 158:2932-2938 (1997).
Tracey, Kevin J. et al., “Tumor Necrosis Factor: A Pleiotropic Cytokine and Therapuetic [sic] Terget,”Annu. Rev. Med., 45:491-503 (1994).
Galle, Peter R. et al., “Involvement of the CD95 (APO-1/Fas) Receptor and Ligand in Liver Damage,”J. Exp. Med., 182:1223-1230 (1995).
Sato, Ken et al., “An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand,”British Journal of Haematolog, 94:379-382 (1996).
van Oers, M. H. J. et al., “Expression and Release of CD27 in Human B-Cell Malignancies,”Blood, 82:3430-3436 (1993).
Smith, Matthew M. et al., “Rapid Identification of Highly Active and Selective Substrates for Stromelysin and Matrilysin Using Bacteriophage Peptide Display Libraries,”The Journal of Biological Chemistry, 270:6440-6449 (1995).
Nagase, H. et al., “Human Matrix Metalloproteinase Specificity Studies Using Collagen Sequence-Based Synthetic Peptides,”Biopolymers(Peptide Science), 40:399-416 (1996).
Cantwell, Mark J. et al., “Adenovirus Vector Infection of Chronic Lymphocytic Leukemia B Cells,”Blood, 88:4676-4683 (1996).
Woll, P. J. et al., “Gene therapy for lung cancer,”Annals of Oncology, 6 Suppl. 1:S73-S77 (1995).
Smith, K. T. et al., “Gene delivery systems for use in gene therapy: an overview of quality assurance and safety issues,”Gene Therapy, 3:190-200 (1996).
Cooper, Mark J., “Noninfectious Gene Transfer and Expression Systems for Cancer Gene Therapy,”Seminars in Oncology, 23:172-187 (1996).
Shaughnessy, Elizabeth et al., “Parvoviral Vectors for the Gene Therapy of Cancer,”Seminars in Oncology, 23:159-171 (1996).
Glorioso, J. C. et al., “Development and application of herpes simplex virus vectors for human gene therapy,”Annu. Rev. Microbiol., 49:675-710 (1995).
Flotte, T. R. et al., “Adeno-associated virus vectors for gene therapy,”Gene Therapy, 2:357-362 (1995).
Randrianarison-Jewtoukoff, Voahangy et al., “Recombinant Adenoviruses as Vaccines,”Biologicals, 23:145-157 (1995).
Kohn, Donald B., “The current status of gene therapy using hematopoietic stem cell,”Current Opinion in Pediatrics, 7:56-63 (1995).
Vile, R. G. et al., “Retroviruses as vectors,”British Medical Bulletin, 51:12-30 (1995).
Russell, Stephen J., “Replicating vectors for cancer therapy: a question of strategy,”Seminars in Cancer Biology, 5:437-443 (1994).
Ali, Munaf et al., “The use of DNA viruses as vectors for gene therapy,”Gene Therapy, 1:367-384 (1994).
Tesselaar, Kiki et al., “Characterization of Murine CD70, the Ligand of the TNF Receptor Family Member CD27,”The Journal of Immunology, 159:4959-4965 (1997).
Peitsch, Manuel C. et al., “A 3-D model for the CD40 ligand predicts that it is a compact trimer similar to the tumor necrosis factors,”International Immunology, 5:233-238 (1993).
Horton, Robert M., “PCR-mediated Recombination and Mutagenesis,”Molecular Biotechnology, 3:93-99 (1995).
Ali, Stuart Alvaro et al., “PCR-Ligation-PCR Mutagenesis: A Protocol for Creating Gene Fusions and Mutations,”BioTechniques, 18:746-750 (1995).
Vilardaga, J. P. et al., “Improved PCR Method for High-Efficiency Site-Directed Mutagenesis Using Class 2S Restriction Enzymes,”BioTechniques, 18:604-606 (1995).
Majumder, Kumud et al., “Background-minimized Cassette-Mutagenesis by PCR Using Cassette-specific Selection Markers: A Useful General Approach for Studying Structure-Function Relationships of Multisubstrate Enzymes,”PCR Methods and Applications, 4:212-218 (1995).
Boles, Eckhard et al., “A rapid and highly efficient method for PCR-based site-directed mutagenesis using only one new primer,”Curr. Genet., 28:197-198 (1995).
Vallejo, Abbe N. et al., “In Vitro Synthesis of Novel Genes: Mutgenesis and Recombination by PCR,”PCR Methods and Applications, 4:S123-S130 (1994).
Henkel, Thomas et al., “Functional Analysis of Mutated cDNA Clones by Direct Use of PCR Products in in Vitro Transcription/Translation Reactions,”Analytical Biochemistry, 214:351-352 (1993).
Tessier, Daniel C. et al., “PCR-Assisted Large Insertion/Deletion Mutagenesis,”BioTechniques, 15:498-501 (1993).
Morrison, Hilary G. et al., “A PCR-Based Strategy for Extensive Mutagenesis of a Target DNA Sequence,”BioTechniques, 14:454-457 (1993).
Cadwell, R. Craig et al., “Randomization of Genes by PCR Mutagenesis,”PCR Methods and Applications, 2:28-33 (1992).
Stappert, J

Affiliated with

Also associated with

Rating

Methods of expressing chimeric mouse and human CD40 ligand... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of expressing chimeric mouse and human CD40 ligand..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of expressing chimeric mouse and human CD40 ligand... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3607235